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1. Introduction 
Systemic lupus erythematosus (SLE) (OMIM #152700) is the prototype of a multiorgan 
autoimmune disease and still considered as a disease with an ambiguous etiology. The 
disease predominantly affects women during the reproductive years at a ratio of eight 
women per one man (Lopez, 2003). Its pathogenesis is multifactorial lying on genetic and 
environmental factors in which it occurs in genetically-predisposed individuals who have 
experienced certain environmental triggers resulting in an irreversible loss of immunologic 
self-tolerance. The nature of these environmental triggers is largely unknown. It is most 
likely that it requires a number of environmental triggers occurring together or sequentially 
over a limited period of time. The concept has therefore emerged of ‘threshold liability’ in 
which disease develops when a threshold of genetic and environmental susceptibility effects 
is reached (Jönsen,2007). Epigenetics, the control of gene packaging and expression 
independent of alterations in the DNA sequence, is providing new directions linking 
genetics and environmental factors. It has become clear that besides genetics, epigenetics 
plays a major role in complex diseases with complex immunological pathogenesis like 
lupus. Convincing evidence indicates that epigenetic mechanisms, and in particular 
impaired T cell DNA methylation, provide an additional factor. Interpreting the precise 
contribution of epigenetic factors to autoimmunity, and in particular to SLE, has become an 
active research area. 
Herein, we will discuss our current understanding of SLE as an autoimmune disease and as 
a complex genetic disorder. Through the review of the current list of best validated SLE 
disease susceptibility candidate genes, in particular considering how the known and 
potential function of these genes may allow us to articulate the genetic of SLE pathogenesis. 
In addition we will review the effect of epigenetics on SLE pathology. 
1.1 SLE, the disease  
This complex autoimmune disease results on defects of multiple immunologic components 
of both the innate immune system and the adaptive immune system including altered 
immune tolerance mechanism, hyperactivation of T and B cells, decreased ability to clear 
immune complexes and apoptotic cells, and failure of multiple regulatory networks 
(Firestein, 2008). Moreover it is likely that immunological dysfunction precedes the onset of 
clinical disease by many years, making it a particularly challenging disease to study 
(Arbuckle, 2003). 
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SLE is a heterogeneous disease that has a diverse range of clinical symptoms, resulting from 
a widespread immune-mediated damage and it is presented differently from patient to 
patient (Arnett, 1988). The most common clinical manifestations of this disease include an 
are erythematous rash, oral ulcers, polyarthralgia, polyserositis, nonerosive arthritis, renal, 
hematologic, neurologic, pulmonary and cardiac abnormalities. Eleven criteria were 
identified for SLE clinical presentation, at least four of the 11 coded criteria need to be 
present for a clinical diagnosis of SLE (Arnett, 1988; Hochberg, 1997; Tan, 1982). Ethnic and 
genetic heterogeneity contributes to the complexity in SLE clinical presentation. Differently 
from Multiple sclerosis and although the disease is progressive in nature, no severity criteria 
have been developed to subgroup SLE patients (with the exception of kidney disease) (Tsao, 
1998). A more detailed classification of SLE this heterogeneous disease would significantly 
help in its genetic analysis. Analyses conditioned on specific disease traits suggest that 
genetic effects arising from particular linkage regions may contribute to specific clinical or 
immunological features of SLE (i.e. the presence of haemolytic anaemia or the production of 
dsDNA antibodies) (Ramos, 2006; Hunnangkul, 2008). A similar picture has arisen from the 
study of mouse models. However, now it is widely accepted that SLE occurs in phases 
during a period of time that can be also of years. Therefore, the following steps in the 
development process of SLE have been suggested: i) genetic predisposition, ii) gender as an 
additional predisposing factor, iii) environmental stimuli which start immune responses, iv) 
appearance of autoantibodies, v) regulation of the autoantibodies, T and B cell fails with the 
development of the clinical disease, vi) chronic inflammation and oxidative damage as 
causes of tissue damage influencing morbidity (Gualtierotti, 2010). 
1.2 Genetic contribution in the pathology of lupus 
A genetic contribution to human lupus is well established. The strong genetic contribution 
to the development of SLE is supported by the high heritability of the disease (>66%), a 
higher concordance rate for SLE in monozygotic twins than in dizygotic twins or siblings 
(24–56% versus 2–5%, respectively) which was observed over 30 years ago, and the high 
sibling recurrence risk ratio of patients with SLE (between eightfold and 29-fold higher than 
in the general population) and up to 10% of SLE patients have a relative with lupus 
(Deapen, 1992). Clustering of SLE is fairly rare occurring only in 1/1000-2000 cases. Except 
in the rare cases of complement deficiency, the inheritance pattern of SLE does not follow 
simple Mendelian rules as we would expect for a single major gene effect, instead a 
polygenic model of susceptibility provides the best explanation for the familial clustering. 
Suggesting that genetic risk in most lupus patients arises from the combination of a number 
of relatively common variations in several different genes, each of these variations have a 
modest effect size, contribute to disease genesis. Despite this knowledge, however, it is a 
challenge to fully understand the genetic pathogenesis of the disease. This is essentially 
because SLE features a polygenic genetic model, which according to today’s evidence may 
involve as many as 100 genes, and every gene only has a moderate effect size. Genetic 
studies can enhance our understanding of disease pathogenesis better. During the past few 
years, progress in biomedical science, bioinformatics, and experimental technology has 
given us new tools rapidly advanced our understanding of the genetic basis of systemic 
lupus erythematosus (SLE) and allowed a deeper investigation of SLE genetics and 
genomics. High throughput genotyping/sequencing platforms, high-throughput 
expression-level study technologies, etc., have brought forth many new insights. In 
particular, the genome-wide association study (GWAS) approach, with its ability to screen 
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hundreds of thousands of SNPs across the genome without previous knowledge of 
candidate regions or genes, has not only supported some findings from previous candidate 
gene studies, but also discovered convincing evidence for novel genetic loci that may be 
implicated in SLE (Hardy, 2009; Hirschhorn, 2009). Although the number of genes involved 
in susceptibility to SLE is increasing in number with the advances in research and 
technology, however, the complete list of genes that fully account for disease susceptibility 
is not completed yet. Table1 represents the top SLE candidate genes categorized by 
chromosomal location.  
Most of the genes proven to be associated with susceptibility to SLE are involved in three 
types of biological process: 1) immune complex processing, 2) toll-like receptor function and 
type I interferon production, and 3) immune signal transduction in lymphocytes. Several 
genes without an obvious immunologic function in SLE have been discovered from recent 
GWA studies  such as: KIAA1542, PXK, XKR6, ATG5, etc. (Harley, 2008). These novel gene 
(loci) discoveries, which are assumed the most powerful and interesting results from GWA 
studies, can lead us to new pathways or mechanisms that we previously didn’t know. The 
genetic heterogeneity between ethnic populations has been suggested to be important in 
SLE risk (Yang, 2009), showing the need for further GWAS in the various populations. 
Genetic loci for SLE in an ethnic group are not always replicated in the other ethnic groups, 
especially between Whites and Asians (Kim, 2009). However, some loci have been shown 
consistent associations across ethnicities such as; HLA-DRB1, FCGRs (FCGR2A and 
FCGR3A), STAT4, and IRF5, BLK, TNFAIP3, BANK1, and MECP2, providing common 
mechanisms in the development of SLE across ethnic groups. For example: In a large 
collection of different ethnic groups including European American, Korean, African 
American, and Hispanic American, relatively high-density genotyping across STAT1 and 
STAT4 genes has confirmed the association of multiple STAT4 SNPs and common risk 
haplotypes with SLE in multiple racial groups (Namjou, 2009). 
The ethnical diversity in gene association with SLE can be explained due to various reasons: 
First, different genetic backgrounds in the various populations from different ancestries 
result in the different genetic risk factors for the same disease (Namjou, 2009; Kochi 2009; 
Tian , 2008). Second, SLE as most of the complex traits in human are developed by combined 
genetic factors and environmental factors for a long period of time. Third, the other 
explanation of inconsistency in genetic association among populations is that disease-
associated SNP is unlikely to be the causal variant and rather is more likely to be in strong 
LD with the biologically relevant variant (Hardy, 2009; Graham, 2009). To date, since it is 
not feasible to test all variants of human genome even in a GWA study, the aforementioned 
reasons as reasonable explanation of non-reproducible genetic studies between populations. 
1.3 SLE and Copy Number Variation (CNV) and Mendelian forms of SLE 
1.3.1 Copy Number Variation (CNV) 
CNV is exhibited in up to 12% of the human genome (Ku, 2010). Therefore, it is 
increasingly believed that large-scale deletion or duplication of DNA segments is a major 
source of human genetic variation (Ku, 2010). CNVs appear to play an important role in 
several common diseases (International Schizophrenia Consortium, 2008; Sebat, 2007). 
The relative contribution of CNVs, to the genetic component of SLE is unclear. 
Comprehensive studies of CNVs in SLE are expected in the coming years. Although 
evidences of the involvement of CNVs in SLE susceptibility are accumulating, for 
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example; CNV was found in various genes involved in the pathology of SLE such as: the 
Fc receptor region (Fanciulli, 2007), Complement Factor 4 in the HLA class III region 
(Yang,2007), the histamine H4 receptor (HRH4) (Yu, 2010), however, a definitive role for 
the CNV has not been convincingly disentangled from nearby, linked risk variants 
(Fanciulli, 2007; Yang,2007).  
1.3.2 Mendelian manner of SLE 
A number of rare variants that cause SLE in a Mendelian manner have been identified 
throughout the years, including disruption of several complement pathway components 
(Harley, 1998). The Mendelian forms of SLE shed light onto pathways critical in 
pathogenesis, but account for only a small portion of the overall disease incidence (Harley, 
1998). 
2. Genes involved in the susceptibility to SLE 
Herein we will describe the involvement of the key genes involved in the susceptibility to 
SLE. The genes will be introduced according to their location on the chromosomes.  
2.1 Chromosome 1 
There is considerable evidence supporting that multiple genes on this chromosome 
contribute to the development and expression of SLE (Tsao, 2000).   
2.1.1 Fcγ receptors: FCGR2A, FCGR3A, FCGR2B and FCGR3B, (1q23-24)  
The Fragment crystallizable receptors (FcRs) FcǄ receptor family (FCGRs: FCGR2A 
(CD32a); FCGR2B (CD32b); FCGR3A (CD16a) and FCGR3B (CD16b)) are a heterogeneous 
group of hematopoeitic cell surface glycoproteins that bind to the Fc region of 
immunoglobulins and facilitate the efficiency of antibody-antigen interactions with 
effector cells of the immune system. These receptors regulate a variety of cellular and 
humoral immune responses including phagocytosis, immune complex clearance, 
degranulation, antibody-dependent cellular cytotoxicity, transcriptional regulation of 
cytokine and chemokine expression, and B cell activation. The cellular distribution and Ig 
isotype (IgA, IgD, IgE, IgG and IgM) specificity influence the regulatory roles of Fc 
receptors. In broad terms, FcǄRs can be classified into high or low affinity receptors based 
on their affinity for IgG or into activating (FcǄRI, FcǄRIIA/C, FcǄRIII) or inhibitory 
(FcǄRIIB) receptors based on their signaling activity and associated functions as they 
stimulate or inhibit immune functions such as phagocytosis, cytotoxicity, degranulation, 
antigen presentation and cytokine production via immune tyrosine activating or 
inhibitory motifs (ITAM or ITIM). In humans, three major classes of IgG-receptor have 
been described; FcRI (CD64), FccRII (CD 32), and FcǄRIII (CD16). These classes can be 
further sub-divided into discrete isoforms such as FcǄRIIA, FcǄRIIB, FcǄRIIC, FcǄRIIIA 
and FcǄRIIIB that exhibit significant differences in their affinity for individual IgG sub-
classes and tissue distribution. One of the difficulties of studying the Fc-receptor region 
on chromosome (1q23-24) is the high level of sequence similarity between each of the Fc-
receptor genes suggests that the whole Fc-receptor gene cluster arose from the 
duplication of a single ancestral gene. Another complicating factor at this locus is the 
presence of copy number variation (CNV).  
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In human patients as well as in experimental animal models, FcǄRs have been implicated in 
immune dysfunction and the development of autoimmunity. The best correlation between 
impaired FcǄRs function and autoimmune pathogenesis is seen in systemic lupus. Various 
functional variants in FCǄR2A, FCǄR2B, and FCǄR3A have been identified as risk factors for 
SLE (Nimmerjahn, 2008). These variants might lead to the defective clearance of immune 
complexes from the circulation therefore will contribute to the deposition in tissues such as 
the kidney and blood vessels (Lehrnbecher, 1999a; Tsokos, 2001).   
FcγRIIA receptor contains ITAM on cell membranes of neutrophils, monocytes, 
macrophages, dendritic cells and platelets. It is the major receptor for the IgG2 subclass, 
which is a poor activator of classical complement pathway. It is the only FcR for clearing 
IgG2-bound immune complexes. The association of FCGR2A alleles with SLE has been 
studied intensively in several populations (Brown, 2007). Mutations in FCGRs have been 
shown to alter the function of monocytic cells and B-lymphocytes. For example; the 
nonsynonymous SNP which result in the substitution of Arginine at amino acid position 131 
(R131) of FCGR2A (R131; rs1801274) to Histidine within the ligand binding domain of 
FcγRIIa diminishes binding to IgG2 results in impaired IgG2-mediated phagocytosis 
(Parren, 1992a,b; Warmerdam, 1991a,b; Clark, 1991; Salmon, 1996). FcǄRIIA R131, might 
contribute to the risk of proliferative lupus nephritis by activating phagocytes, releasing 
proinflammatory cytokines and reduced clearance of immune complexes (ICs) (Bredius, 
1993; Karassa, 2002). Karassa et al. conducted a meta-analysis regarding this polymorphism 
which included 17 studies, involving a total of 3114 SLE patients and 2580 non-SLE controls 
of European, African, and Asian descent, demonstrating that the R131 allele was associated 
with SLE (Karassa, 2002). In other studies conducted in Asians, it has been shown that the 
FCGRIIA-R131 allele was correlated with certain disease phenotypes. Kobayashi et al. 
studied Japanese SLE patients with or without periodontitis, and found that the R allele was 
significantly correlated (Kobayashi, 2007). Siriboonrit et al. also found in a Japanese cohort that 
the R allele was significantly increased in patients with lupus nephritis (Siriboonrit, 2003). In 
various ethnic groups (Europeans, African Americans and Koreans), R131 (rs1801274) showed 
inconsistent association with susceptibility to SLE, lupus nephritis, or both (Duits, 1995; Yap, 
1999; Chen, 2004; Salmon, 1996; Song, 1998). Ethnic differences, disease heterogeneity, 
genotyping error due to extensive sequence homology among FCGR genes and random 
fluctuations in small samples might explain these inconsistent associations. 
FcγR3IIIA receptor contains ITAM on cell surfaces of natural killer (NK) cells, monocytes, 
and macrophages. FcǄR3A alleles with differential affinity for IgG1 and IgG3 have also been 
shown to be associated with SLE patients from ethnically diverse groups (Yap, 1999).  The 
nonsynonymous SNP, where valine (V158) of FcǄRIIIA changes to phenylalanine (F158) 
(rs396991) was shown to reduce the IgG1-, IgG3-, and IgG4-binding capacity of the receptor 
compared to V/V homozygotes. This polymorphism, normally termed FcǄRIIIA-176 F/V or 
FcǄRIIIA-158 F/V when excluding the leader sequence, was first reported to be of 
significant correlation with SLE in the Asian population (Japanese) by Kyogoku et al 
(Tsuchiya, 2005). Studies in human cohorts have shown that SLE is significantly associated 
with both alleles, R131 and F158, that encode lower affinity isoforms of FcǄRIIA and 
FcǄRIIIA respectively (Lehrnbecher, 1999b). F158 homozygotes bind IgG1- and IgG3-
containing ICs less efficiently than V 158 homozygotes, and confers less efficient clearance of 
ICs than other alleles was associated with SLE susceptibility(Koene, 1998). However, the 
association between FcǄR3A-V/F158 polymorphism and susceptibility to SLE and/or lupus 
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nephritis has been variable in several studies (Tsao, 2004). A meta-analysis of more than 
1,000 subjects in each of the three categories (SLE without or without renal involvement, and 
non-SLE controls) has concluded that the F158 allele confers a 1.2-fold risk for developing 
lupus nephritis in patients of European, African, and Asian descent but not for SLE 
susceptibility without renal involvement (Karassa, 2003). 
The FcǄRIIA-R131 and FcǄRIIIA-F158 are often inherited together on the same chromosome 
as a single-risk haplotype for SLE (Magnusson, 2004). The presence of multiple risk alleles 
might interact to enhance the risk for SLE (Sullivan, 2003). The relative importance of 
FcǄR2A-H/R131 and FcǄR3A-V/F158 to disease progression might depend on the IgG 
subclass of pathogenic auto antibodies in an individual patient.  
A novel polymorphism in FCGR3A, the rs403016 located in the Exon 3 which causes a 
non-synonymous substitution, the FCGR3A-72R/S, has been found to be associated with 
SLE in a Chinese SLE cohort, where the R allele contributes to disease susceptibility (Ye, 
2006; Pan, 2008). 
In a meta-analysis carried out by Lehrnbecher et. al., the development of SLE was 
significantly associated with the alleles encoding the low affinity isoforms of both 
FcǄRIIA (FcǄRIIA–R/R131) and FcǄRIIIA (FcǄRIIIA–F/F158) (Lehrnbecher, 1999b). More 
recently, a similar meta-analysis study carried out by Karassa and colleagues found that 
an FcǄRIIA–R/H131 polymorphism represents a significant risk factor for the 
development of SLE but had no clear effect on susceptibility for lupus nephritis in a large 
patient cohort (Karassa, 2002). 
Lower level evidence exists for a non-synonymous mutation in FcǄRIIIA proposed to alter 
IgG binding affinity, a promoter SNP in FCGR2B that alters transcription factor binding and 
receptor expression and, in Asian populations, a non-synonymous SNP in exon 6 of 
FCGR2B suggested to influence B-cell activation (Brown, 2007).  
FcγRIIB: FCGR2B receptor is expressed on B cells, dendritic cells, monocytes/macrophages, 
and mast cells. It contains an ITIM that regulates B-cell survival and proliferation by down-
modulating B-cell receptor signaling, and by decreasing antibody-mediated phagocytosis in 
macrophages (Daeron, 1997).  
A nonsynonymous SNP in the transmembrane domain of FcǄRIIB (Ile187Thr) that alters the 
inhibitory function of FcǄRIIB on B cells is associated with SLE in Asian populations,( 
Kyogoku, 2002; Siriboonrit, 2003; Chu, 2004) but not in other populations partly owing to 
their low allele frequencies (Li, 2003; Kyogoku, 2004; Magnusson, 2004). The FcǄR2B 
encoded by the Thr187 allele results in impaired inhibition of B-cell activation and promotes 
autoimmunity (Floto, 2005). A functional promoter haplotype (–386G/–120T) of FcǄRIIB 
that confers increased transcription of FcǄRIIB has been associated with 1.6-fold risk for SLE 
in Caucasian Americans (Su, 2004). This haplotype is not in LD with FcǄRIIA and FcǄRIIIA 
polymorphisms and is likely to have an independent association with SLE (Kyogoku, 2002). 
FcγRIIIB: FCGR3B is expressed solely on neutrophils. It lacks an ITAM domain, so the 
transmission of intracellular signals is likely to involve cooperation with other 
transmembrane proteins. Of particular interest are data suggesting that this is achieved 
through an interaction with complement receptor 3/integrin M (Krauss, 1994; Poo, 1995; 
Stockl, 1995). It is considered low affinity receptor for the Fc region of immunoglobulins 
gamma. It binds to complexed or aggregated IgG and also monomeric IgG. Contrary to 
FCǄR3A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. It 
may serve as a trap for immune complexes in the peripheral circulation which does not 
activate neutrophils. 
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Six SNPS exist in FCGR3B, underlying three different allotypic variants of FCGR3B (NA1, 
NA2 and SH). The association reported by Hatta et a.l.( Hatta, 1999) between the NA2 
allotype and SLE in a Japanese population has not been replicated, suggesting that the 
association between SLE and this genomic region might be influenced by other genetic 
variations. Both duplication and deficiency of FCGR3B were reported in normal individuals 
(Clark, 1990; Koene, 1998). The inheritance pattern of FCGR3B in some families affected by 
SLE has suggested that the copy number variation might be the underlying condition.  
The number of copies of FCGR3B in a cell can vary from none to four, with a gene-dose 
effect that reduced FcǄRIIIB copy number being a risk factor for glomerulonephritis in SLE 
patients. In addition, FCGR3B copy number varies significantly with non-Mendelian 
inheritance, suggesting that the association of FCGR3B copy number with lupus nephritis is 
an independent risk factor (Aitman, 2006). Since human FCGR3B is expressed mainly in 
neutrophils, and it is postulated that SLE patients with low FCGR3B copy number have 
reduced neutrophil expression, which leads to reduced glomerular clearance of immune 
complexes, and brings forth susceptibility to SLE and other autoimmune disorders. This 
observation supports that copy number polymorphism at orthologous regions of diverse 
genomes is associated with immunologically related disease. It also suggests that genome 
plasticity, manifested by gene duplication/deletion and copy number polymorphism, is a 
common cause of genetically complex phenotypes. Fc receptor-like genes (FCRLs): FCLs 
clustered at 1q21–22 encode proteins that are structurally homologous classical FCGRs. To 
enhance our understanding of the functional roles of Fcγ receptors in SLE, an integrated 
approach to simultaneously assess CNVs, allotypic variants, SNPs and the functional 
diversity of these receptors in large-scale case–control studies including multiple ethnic 
populations is needed to dissect the relative contribution of various variants in this complex 
FCGR locus to SLE. 
2.2 Protein tyrosine phosphatase non-receptor 22 (PTPN22) (1p13)  
PTPN22 is a negative regulator for T-cell signal transduction in cellular immunity.  It is 
considered to be the strongest common genetic risk factor for human autoimmunity besides 
the major histocompatibility complex (MHC) and as an important candidate gene in SLE. A 
number of candidate gene studies found (SNP rs2476601) R620W polymorphism in the 
proximal protein-rich SH3-binding domain (+1858T/C), to be associated with the increased 
risk of SLE (Orozco, 2005). This has been confirmed in a meta-analysis (Lea, 2011) and SLE 
GWA analysis. This polymorphism was found to be associated with several autoimmune 
diseases in Caucasians, including T1D, autoimmune thyroid disease, RA and SLE, but not 
with multiple sclerosis (MS). SNP rs2476601 is not polymorphic in Koreans and Japanese 
and almost absent in African populations (Gregersen, 2006) while it is more common in 
northern Europeans (8–15%) compared with southern Europeans (2–10%) (Gregersen, 2009). 
Suggesting the presence of genetic heterogeneity across various ethnicities. 
The lymphoid tyrosine phosphatase protein (LYP), which is encoded by PTPN22, is known 
to regulate immunological synapse formation. LYP is involved in the down-regulation of  
T-cell activation through its interaction with a negative regulator of TCR signaling C-
terminal Src tyrosine kinase (Csk); this interaction is prevented by the arginine to 
tryptophan amino acid substitution consequent upon the associated mutation rs2476601 
R620W (C1858T) (Begovich, 2004; Bottini, 2004).  
One would expect this R620W substitution to result in increased T-cell signaling and 
activation; however, experimental evidence suggests the opposite with TCR signaling 
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actually reduced in cells carrying the tryptophan variant protein (Vang, 2005). A number of 
explanations have been proposed including an effect of the mutation on the tyrosine 
phosphatase activity of LYP, or an effect on the binding of other ligands or the conformation 
of LYP in response to these ligands (Vang, 2008). At a cellular level the mechanism by which 
reduced T-cell activation may actually increase the potential for autoimmunity remains a 
matter for speculation, although the suppression of regulatory T-cells is a possibility (Vang, 
2008). A connection between PtPn22 and the type I IFN pathway has been suggested on the 
basis of elevated serum IFN-ǂ activity and decreased tumor necrosis factor (TNF) levels in 
patients with SLE carrying the rs2476601 risk allele (Kariuki, 2008). By contrast, another 
PTPN22 polymorphism, the loss-of-function mutation Arg263Gln in the catalytic domain 
(R263Q), leads to reduced phosphatase activity of PtPn22, and, therefore, increases the 
threshold for TCR signaling has been associated with protection against SLE in European-
derived populations (Orru, 2009). 
2.3 Interleukin 10 (IL 10) 1q32.1 
IL-10 is an important immunoregulatory cytokine in man with both immunosuppressive 
and immunostimulatory properties (Mosmann, 1994).  It is characterized with anti-
inflammatory and stimulatory activities, and plays a critical role in the regulation of cellular 
and humoral immune responses. IL-10 is also involved in the pathology of human 
autoimmune disease (Llorente, 1994; Cash, 1995; Perez, 1995), particularly in the 
dysregulation of B-cell function in systemic lupus erythematosus leading to autoantibody 
production (Itoh, 1995; Llorente, 1995). In addition, its ability to induce T-cell anergy 
(Luscher, 1994) and inhibit major histocompatibility complex class-I expression (Matsuda, 
1994) may be important in its apparent contribution to tumor-related immunosuppression 
(Kim, 1995; Suzuki, 1995; Fortis, 1996). 
It has been known that IL10 production is under strong genetic influence (Westendorp, 
1997). Two CA-repeat microsatellites, IL10R (-4 kb) (GeneBank accession number AF295024) 
and IL10G (-1.1 kb) (GeneBank accession number X78437), and single nucleotide 
polymorphisms (SNPs) were reported in IL10 promoter that has potential association with 
IL10 production. These SNPs are located at positions -A3575T, -A2849G, -A2763C, -A1082G, 
-C819T, and -A592C from the transcription start site. It has been known that -A1082G,  
-C819T, and -A592C combined to form three haplotypes; GCC, ACC, and ATA linked with 
different IL10 expression level (Crawley, 1999). 
IL-10 has been associated in the pathogenesis of SLE; Increased IL10 production by 
peripheral blood B cells and monocytes from patients with SLE is known to correlate with 
disease activity (Hagiwara, 1996), increased IL-10 productions promotes B-cell hyperactivity 
and autoantibody production (Llorente, 1995). The association between IL10 promoter 
haplotypes (defined by three SNPs in the IL10 promoter region -627CA, -854CT and  
-1117GA. These single base-pair substitutions produce three different haplotypes, GCC, 
ACC and ATA,) (Turner, 1997; Eskdale, 1997a) and SLE has been have been reported in 
European, Hispanic American and Asian populations (Eskdale, 1997b; Mehrian, 1998; 
Chong, 2004). A large-scale replication study in populations from the USA and Sweden has 
confirmed IL10 as a SLE susceptibility locus (Gateva, 2009). However, they were found to 
have significant association with lupus nephritis.  
Levels of IL-10 secretion have been correlated to specific IL10 promoter polymorphisms; a 
study has shown that the SNP haplotypes in the distal promoter of IL-10 correlate with 
different IL-10 production phenotype in normal individuals, and high IL-10 haplotype is 
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associated with SLE in African-Americans, which may be a part of their genetic 
susceptibility to SLE. A meta-analysis of 15 IL-10 studies has shown that the G11 allele is 
associated with SLE in whole studied populations, and among the promoter SNPs, −A1082G 
polymorphism, which is found in Asian population only, was also associated with SLE 
(Nath, 2005). Based on these analyses, IL-10 polymorphisms confer SLE risk in an ethnicity-
specific manner (Gateva, 2009; Eskdale, 1997; Mehrian, 1998; Chong, 2004). 
2.4 Complement receptor 1 (CR1, CD35), (1q32)  
Genome scans have shown linkage (lod score >1.0) at chromosome 1q32, which contains 
complement components, like complement receptor 1 (CR1), complement receptor 2 (CR2), 
and C4b-binding protein (C4BP) genes and IL10 family members; IL10, IL19, IL20, and IL24, 
which play a significant role in the pathogenesis of SLE (Johanneson, 2002; Tsao, 1999). The 
C3b/C4b complement receptor (Gene ID: 1378) (CR1, CD35) is a polymorphic 
transmembrane single chain glycoprotein expressed on red cell surface binds to C3b and 
C4b and clears circulating C3- and C4-bearing immune complexes containing (Dykman, 
1984). 
Functional and structural polymorphisms of CR1 have been reported. The functional 
polymorphism determines the quantitative expression of CR1 on erythrocytes, i.e. HH, HL, 
and LL (H = allele correlated with high expression, L = low) (Wilson, 1986). The structural 
polymorphism exists in its molecular size (Dykman, 1983). The extracellular portion of the 
CR1 molecule consists of three to five groups of seven short consensus repeats termed long 
homologous repeats (LHR). The most frequent type of CR1 (F or A) is comprised of four 
extracellular LHRs and expresses one binding site for C4b and two binding sites for C3b 
(Wong, 1983). The S (or B) variant of CR1 is characterized by additional C3b binding site on 
a fifth LHR (Wong, 1989). A meta-analysis for the CR1 functional polymorphisms in SLE 
shows no significant association of CR1 L allele, L/L genotype, and L/L+L/H genotypes 
with SLE. However, the same meta-analysis of CR1 structural polymorphisms suggested an 
association of CR1 S (structural variant of CR1) to be associated with SLE in Caucasians 
(Nath, 2005). 
2.5 Tumor necrosis factor (ligand) SuperFamily, member 4(TNFSF4), 1q25 
TNFSF4 (also known as OX40L; 1q25) encodes a cytokine that is expressed on CD40-
stimulated B cells, activated antigen-presenting cells (APCs) and vascular endothelial cells. 
Also its unique receptor, TNFRSF4 (also known as OX40; 1p36), is primarily expressed on 
activated CD4+ T cells. Their interaction induces the production of CD28-independent  
co-stimulatory signals to activate CD4+ T cells (Baum, 1994). OX40L-mediated signaling 
inhibits the generation and function of IL-10-producing CD4+ type 1 regulatory T cells, but 
induces B-cell activation and differentiation, as well as IL-17 production in vitro (Ito, 2006a; 
Li, 2008).   
These two tumor necrosis factor (TNF) superfamily members (OX40L and OX40) located 
within proximal intervals showing genetic linkage with SLE (Cunninghame, 2008; Chang, 
2009; delGado-Vega, 2009).TNFSF4 has been identified as a susceptibility gene for SLE in 
multiple studies. Protective and risk haplotypes at TNFSF4 were identified in a study of two 
cohorts from Minnesota and UK, a haplotype in the upstream region of TNFSF4, marked by 
SNPs rs844644 and rs2205960, has been shown to correlate with increased cell surface 
TNFSF4 expression and TNFSF4 transcript and to be associated with SLE (Graham, 2008). 
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Associations between some TNFSF4-tagging SNPs and an increased risk for SLE have been 
confirmed in GWAS in Chinese populations and in a European replication study; these 
results were also replicated in four independent SLE datasets from Germany, Italy, Spain 
and argentine. It has not been fully established how TNFRSF4/ TNFSF4 interactions 
influence T-cell subset profiles. Most evidence suggests a bias towards a Th2 pattern of 
cytokine release, although there is also evidence for a down-regulation of regulatory T-cell 
subsets (Ito, 2006b; Lane, 2000). There is also good evidence that signaling through TNFSF4 
can induce B-cell activation and differentiation (Stuber, 1995&1996). TNFRSF4/ TNFSF4 
signaling is therefore bi-directional, and the precise immunological consequences of this 
complex pathway are yet to be clarified. Further studies are needed to localize causal 
variants and to understand how these polymorphisms affect the pathogenesis of SLE. 
2.6 C-reactive protein (CRP), 1q23.2 
CRP is a sensitive marker of inflammation. The genes for CRP (CRP) map to 1q23.2 within 
an interval linked with SLE in multiple populations. It is hypothesized that polymorphism 
of CRP gene contributes to susceptibility to systemic lupus erythematosus (SLE).  
Basal levels of CRP were influenced independently by two polymorphisms at the CRP locus, 
CRP 2 and CRP 4. Furthermore, the latter polymorphism was linked/associated with SLE 
and antinuclear autoantibody production. Thus, the polymorphism associated with reduced 
basal CRP was also associated with the development of SLE. 
CRP is normally involved in phagocytosis of apoptotic debris and immune complexes in 
innate immune response. Defective clearance of products of apoptosis may be the source of 
autoantigens in SLE, and such phenomenon may also be enhanced by FcǄR2A 
polymorphisms, with FcǄR2 receptor being the main receptor for CRP (Bharadwaj, 1999).  
During the active phase of SLE, despite the presence of marked tissue inflammation, CRP 
levels are abnormally low due to reduced synthesis (Russell, 2004). Family-based studies of 
association and linkage have identified the minor allele of rs1205 in the 3’UTR SNP of CRP 
to be associated with SLE and antinuclear antibody production (Russell, 2004), and the 
number of CA repeats correlated with disease risk in a Spanish cohort (Russell, 2004). Also, 
a single dose of CRP has recently shown to reverse lupus nephritis and nephrotoxic 
nephritis in mice, suggesting the acute-phase response of CRP may hinder tissue 
inflammation and damage (Rodriguez, 2005). These results are promising, and future 
investigation of this gene will not only allow better understanding of the genetic influence of 
CRP but also its pathophysiology and possible therapeutic options. 
Two of several polymorphisms in the CRP gene, designated CRP2 (G/C) and CRP4 (G/A) 
have been demonstrated to have an impact on baseline serum concentration of CRP, with 
the C- and A-alleles being associated with lower concentrations (Russell, 2004). 
Furthermore, the CRP4 A-allele was shown to confer increased susceptibility to SLE in 586 
families (P=0.006) (Russell, 2004). The A allele at CRP 4 had a relatively high frequency in 
European and Asian-Indian populations (∼0.3) and was present in Afro-Caribbean families 
too, but at a lower frequency (0.14). 
2.7 Poly(ADP-ribose) polymerase (PARP), (1q41–42) 
PARP is an enzyme (PARP-1 EC 2.4.2.30) is induced by DNA strand breaks caused by 
several agents and utilizes NAD to form polyADPR, bound to acceptor proteins. It is 
responsible for DNA repair, proliferation, stress response, apoptosis, and genomic stability 
(Oliver, 1999). The involvement of PARP-1 in autoimmune diseases has been suggested 
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especially in systemic lupus erythematosus (SLE) due to the decreased levels of activity and 
mRNA in SLE patients (Haug 1994). Autoantibodies to PARP are frequently found in 
patients affected with autoimmune diseases, some of which may prevent caspase-3-
mediated PARP cleavage during apoptosis, resulting in the accumulation of autoimmune 
cells (Decker, 2000). On chromosome 1q41–q42 a 15-cM region has been linked with 
susceptibility to SLE (Tsao, 1997), this linkage has been confirmed in several independent 
studies. In a family-based TDT analysis, PARP alleles had skewed transmission to affected 
offspring, but this finding is not consistent in other multi-ethnic studies (Tsao, 1999).  
A polymorphic CA tandem repeat within the PARP promoter region suggested to affect 
transcription activity has been associated with SLE in some but not other similar studies 
(Oei, 2001). A study investigated the association of PARP promoter CA tandem repeats 
polymorphisms with SLE susceptibility in Taiwan. Nine alleles ranging from 12 to 20 
repeats were disclosed. No statistically significant association with SLE susceptibility was 
found in this population however; PARP microsatellite polymorphisms demonstrate 
associations with clinical subphenotypes such as discoid rash and arthritis, anti-cardiolipin 
IgG and anti-ds-DNA antibody production. These indicate that PARP CA repeats may play 
a key role in lupus pathogenesis involving DNA repair of cell damage and consequent 
autoantibody production. Tsao et al demonstrated a skewed transmission of PARP alleles in 
a family study with the PARP CA8 allele as susceptible and the PARP CA14 allele as a 
protector of lupus transmission (Tsao, 1999). 
In a Korean study, PARP polymorphisms could not prove any statistically significant 
association with the risk of SLE was observed, however, they found that two single-
nucleotide polymorphisms (SNPs -1963A/G and +28077G/A) were significantly associated 
with an increased risk of nephritis, and one non-synonymous variant [+40329T/C (V762A)] 
was also significantly associated with an increased risk of arthritis, while the -1963A/G 
polymorphism showed a protective effect on arthritis in Korean SLE patients (Hur, 2006). 
2.8 Toll-like receptor 5 (TLR5), 1q41–q42 
At least 10 different TLR have been cloned from the human genome to date. Toll-like 
receptors (TLR) are type I transmembrane proteins contain an extracellular leucine-rich 
region involved in pathogen recognition and a conserved intracellular Toll/IL-1 receptor 
domain that activates a signaling pathway. Stimulation of the TLR pathway ends in NF-B 
activation and transcription of immune response genes, such as cytokines and chemokines. 
TLRs play an important role in the activation and regulation of both adaptive and innate 
immunity. They are considered as excellent candidate genes for genetic susceptibility 
studies for autoimmune diseases. TLR5 is a critical regulator of inflammatory pathways and 
maps to chromosome 1q41. Activation of TLR5 triggers production of proinflammatory 
cytokines, such as IL-6, which, in turn, can stimulate B cells to proliferate, differentiate, and 
secrete antibodies. Dysregulation of this process may lead to excessive production of 
cytokines as well as autoantibodies (Dean, 2000). 
It was hypothesized that the stop codon variant C1174T (rs5744168) (Arginine to a stop 
codon at position 392 (R392X) in TLR5, is associated with susceptibility to SLE. This 
hypothesis was tested by using a TDT in a Caucasian SLE cohort and found that the TLR5 
stop codon polymorphism, but not other TLR5 alleles, is associated with protection from 
developing SLE as subjects with 1174T produced less proinflammatory cytokines (IL-6, 
TNF-ǂ, and IL-1ǃ) (Hawn, 2003; Hawn, 2005). In addition the same group found that this 
association was most pronounced in individuals who are seronegative for anti-dsDNA 
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autoantibodies (Tsao, 1999; Hawn, 2005). TLR5R392X may provide protection from SLE by 
decreasing production of proinflammatory cytokines during infection with flagellated 
bacteria, which may influence formation of the adaptive immune response. These results 
suggest a role for the innate immune response in the development of SLE that involves 
flagellated bacterial infections. 
3. Chromosome 2 
Locus 2q32- q37 encodes the Programmed cell death 1 gene (PDCD1), Cytotoxic T-
lymphocyte associated protein 4 (CTLA4) and STAT4 transcription factor. All were proven 
to be associated to susceptibility to SLE.  
3.1 Programmed cell death 1 gene (PDCD1/ CD279) (2q37)  
PDCD1 codes for an immunoreceptor, PD-1, member of the CD28/CTLA4/ICOS co-
stimulatory receptor family that bears an inhibitory immunoreceptor tyrosine-based motif 
(ITIM). It is expressed on activated T- and B-cell surfaces to regulate their peripheral 
tolerance (Agata 1996; Finger, 1997). PDCD1 is upregulated in T cells following activation, 
and inhibits TCR signaling and T/B cell survival. It is considered a strong candidate for SLE 
association. 
The human PDCD1 has an intron enhancer which contains binding sites for other 
transcription factors that are involved in lymphocyte development and T cell differentiation. 
PDCD single nucleotide polymorphism (SNP) (PD1.3A, the minor A allele of 7146 G/A) in 
this intron enhancer alters a binding site for the runt-related transcription factor (RUNX1). 
The PDCD1 enhancer has a very high GC content (from 50 to 75%). The A allele of the 
PDCD1 enhancer SNP changes a potential methylation site from CpG to CpA that is 
surrounded by many other potential methylation sites. Methylation is a known mechanism 
of regulation of gene activity (Avni, 2000). Whether methylation is involved in the 
regulation of PDCD1 is under investigation. Changes in methylation can condition the 
developmental stage of PDCD1 expression. 
SNP 7146 G/A was shown to be association with SLE susceptibility and its contribution to 
SLE development was confirmed in Europeans and Mexicans by inducing lymphocytic 
hyperactivity in these patients (Prokunina, 2002). PDCD-1 polymorphisms may be a shared 
genetic factor for multiple autoimmune diseases in humans, and the cellular function 
leading to disease onset awaits further investigation. PDCD1 7209 CT or 7209 TT genotype 
exhibited 3.28-fold increased risk of SLE in the Polish and Taiwanese populations 
(Mostowska, 2008). 
The most logical explanation of the mechanism of disease susceptibility for PDCD1 was 
suggested by Alarcón-Riquelme M et al (Alarcón-Riquelme, 2003); The stated: “So what 
effects could the aberrant function or expression of PDCD1 have in early lymphocyte 
differentiation that may lead to autoimmune disease, in particular SLE? It mainly depends 
on at what stage of differentiation does the RUNX1–PDCD1 interaction take place whether 
it occurs before clonal receptor rearrangements or after. As PDCD1 seems to act during 
positive selection in the thymus, at least in the mouse, this leads us to suggest that the 
human mutation may be promoting positive selection of early autoreactive progenitors, 
leading to an increased “susceptibility” to expand autoreactive T or B cells after antigenic 
stimuli, however the amount of information to date on PDCD1 in lymphocyte development 
and its regulation is still an open question”. 
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3.2 Cytotoxic T-lymphocyteassociated protein 4 (CTLA4), (2q33) 
CTLA4 is a structural homologue of CD28. It is a negative costimulatory molecule that 
inhibits T cell activation, and may help to limit T cell responses under conditions of 
inflammation and prevents autoimmune diseases by promoting anergy. It competes with 
the binding of CD28 on antigen presenting cells (APCs), and transduces inhibitory signals 
by activation of serine/threonine phosphatases. Genetic variability in CTLA4 has been 
implicated in the development of several autoimmune diseases including SLE (Matsushita, 
1999). SLE patients have increased levels of soluble CTLA-4. A single nuclear polymorphism 
(SNP) CT60A/G within the 3’UTR of CTLA4 decreased the production of a spliced variant 
with inhibitory activity, which indicates the importance of CTLA-4 in providing protection 
against autoimmunity (Ueda, 2003). 
SLE in Caucasians, CTLA-4 polymorphisms of its promoter and exon-1 regions was found 
to be associated to SLE. Later, in a Chinese cohort, the CTLA-4 promoter (-1722 T/C) 
polymorphism showed positive evidence (Liu, 2001 & Xu, 2004). However, several genetic 
studies investigating CTLA-4 polymorphisms and SLE have been negative. Among the 
positive studies, different mutations were identified within the CTLA4 promoter 
(−1722T/C, −1661A/G, −319C/T) and exon 1 (+49G/A) in various ethnic groups (Lee, 
2005). More work is needed to delineate the genetic relationship between CTLA-4 and SLE.  
3.3 Signal transducer and activator of transcription 4 protein (STAT4), (2q32) 
STAT4 play key roles in the interferon and Th1 signaling pathway through mediating 
responses to IL-12 in lymphocytes, and regulates T helper cell differentiation. STAT4 also is 
known to mediate signals induced by immunologically relevant cytokines including, like 
IRF5, the Type 1 IFNs (Darnell, 1994 & Watford, 2004). In response to these cytokines, 
STAT4 activation plays an important role in directing a Th1 T-cell response, and mediates 
the production of Th1-type cytokines such as IFN-( Morinobu, 2002; Nguyen, 2002; 
Nishikomori, 2002). In addition, STAT4 signaling also mediates type 1 IFN signaling in 
antigen-presenting cells, and may be necessary for the production of IFN- by these cells 
(Frucht, 2003 & Fukao, 2001). 
STAT4 variation and SLE risk was initially reported in 2007 from a case–control association 
study (Remmers, 2007). This was subsequently confirmed in both GWA studies. Three SNPs 
in STAT4, rs7574865, rs11889341, and rs10168266, were then shown to be in significant 
association with SLE in a Japanese population, with the rs7574865 T allele, in the third intron 
of STAT4, showing the strongest significance. Interestingly, this rs7574865 risk variant is 
associated with a more severe SLE phenotype that is characterized by disease onset at a 
young age (<30 years), a high frequency of nephritis, the presence of antibodies towards 
double stranded DNA, (Taylor, 2008; Kawasaki, 2008; Sigurdsson, 2008) and an increased 
sensitivity to IFN-ǂ signaling in peripheral blood mononuclear cells (Kariuki, 2009). In a 
meta-analysis including Europeans and Asian patients of SLE and RA, the rs7574865 T allele 
was found to be consistently associated with both diseases (Ji, 2010). Possible functional 
relevance of risk STAT4 variant has recently strongly suggested by in vivo experiment in 
SLE patients, in which risk variant of STAT4 (T allele; rs7574865) was simultaneously 
associated with both lower serum IFN-a activity and greater IFN- induced gene expression 
in PBMC in SLE patients. 
A risk haplotype (spanning 73 kb from the third intron to the seventeenth exon of STAT4) 
common to European, Americans, Koreans and Hispanic Americans was also identified 
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(Namjou, 2009). Functionally, either type I IFN or interleukin (IL)-12 induces 
phosphorylation of STAT4, which has a signal transduction role in these pathways. 
Individuals carrying one or more risk alleles of both IRF5 and STAT4 have an increased risk 
for SLE, suggesting a genetic interaction between these two genes (Sigurdsson, 2008).  
The important roles of STAT4 in both innate immunity and Th1 immune response, recent 
enormous body of evidence of consistent association of STAT4 with SLE in multiple racial 
groups indicates that a risk variant or a certain risk haplotype of STAT4 has a crucial role in 
SLE pathogenesis that has yet to be completely determined and could provide new 
therapeutic targets for SLE and the other autoimmune diseases in future. 
4. Chromosome 3 
4.1 Phox homology (PX) domain Kinase (PXK), (3p14.3)  
PXK is of unknown function. PXK domain containing serine/threonine kinase and act as 
modulator of Na, K-ATPase enzymatic and ion pump activities (Mao, 2005). It was 
identified as a novel candidate gene for systemic lupus erythematosus (SLE) from genome-
wide association studies (GWAS) in Caucasians (Suarez-Gestal, 2009). The association of 
PXK rs6445975 with SLE observed in Caucasians was not replication study in Hong Kong 
Chinese and Koreans (Kim, 2011; Yu, 2011; Yang, 2009). It is possible that PXK has different 
genetic contribution on SLE between Caucasians and Asians and that the gene is associated 
with disease subphenotypes rather than with overall susceptibility. 
5. Chromosome 4 
5.1 BANK, BLK and LYN 
All three of these genes play a critical role in controlling the activation of B cells following 
signaling through the B-Cell Receptor (BCR). Following ligand binding and BCR 
aggregation, an early intracellular event is the recruitment and activation of Src-family 
protein tyrosine kinases, including BLK and LYN, which mediate further intracellular 
signaling. The exact role of these kinases in determining cellular events has yet to be 
determined with certainty. 
5.2 B-cell scaffold protein with ankyrin repeats (BANK1), (4q24) 
BANK1 is a B-cell scaffold protein that is tyrosine phosphorylated through the B-cell 
receptor (BCR) upon B-cell activation, which in turn associates with the tyrosine kinase Lyn 
(Src family of tyrosine kinase) and the calcium channel IP3R which results in calcium ion 
release from the stores of the endoplasmic reticulum (Yokoyama, 2002 & Kozyrev, 2008). 
BANK1 is thought to alter B cell activation to increase SLE risk. Polymorphisms in BANK1 
may cause B-cell hyper-responsiveness.  
GWAS in European-derived populations have identified associations of BANK1 and LYN 
with susceptibility to SLE (Kozyrev, 2008 & Guo, 2009). For BANK1 three functional 
variants with either a non-synonymous SNP (rs10516487; Arg61His), a branch point-site 
SNP (rs17266594; located in an intron) or a SNP in the ankyrin domain (rs3733197; 
Ala383Thr) might contribute to the sustained activation of B-cell receptors and the 
subsequent B-cell hyperactivity that is commonly observed in SLE (Kozyrev, 2008). 
However, the best functional evidence was found for rs17266594, which altered a branch 
point upstream of exon 2, resulting in the generation of a novel short isoform, but little 
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quantitative difference in BANK1 expression overall. With the exception of the rs10516487 
SNP of BANK1, which showed a weak association with SLE in an Asian GWAS, the 
remaining SNPS of BANK1 have not been confirmed in either Chinese or Asian GWAS, 
partly owing to the low frequencies of the SNPS in these populations (Chang, 2009). 
6. Chromosome 5 
6.1 TNIP1 (Tumor necrosis factor -induced protein 3 (TNFAIP3) interacting protein 1), 
also known as ABIN (A20-binding inhibitor of NF-B)-1, (5q32-q33.1) 
TNIP1 expression is induced by NF-B, and in turn, overexpression of TNIP1 inhibits NF-
B activation by TNF (Verstrepen, 2009). TNIP1 was shown to inhibit TNF-induced 
apoptosis independently of A20 (Oshima, 2009). Two recent GWAS revealed association of 
TNIP1 intronic SNPs rs7708392 and rs10036748, which are in strong linkage disequilibrium 
(LD) with SLE in the Caucasian (European-American and Swedish) and Chinese Han 
populations, respectively (Han, 2009 & Gateva, 2009). Association of TNIP1 with SLE was 
also confirmed in a Japanese population.  
To date, at least 11 splice variants of TNIP1have been identified (Verstrepen, 2009). Presence 
of alternative exon 1A and 1B, as well as splice variants lacking exon 2, has been described. 
Because rs7708392 is located between exon 1B and exon 2, it is possible that this SNP may 
influence the usage of the splicing isoform. It is also possible that other causative SNPs in 
tight LD with rs7708392 may exist. Such a possibility would be addressed by resequencing 
the entire TNIP1 gene. TNIP1 is a shared SLE susceptibility gene in the Caucasian and Asian 
populations, but the genetic contribution appeared to be greater in the Asians because of the 
higher risk allele frequency in the population. 
7. Chromosome 6 
7.1 Major Histocompatibility Complex (MHC), (6p21.31) 
A body of evidence has been collected to establish the pivotal role of major 
histocompatibility complex (MHC) in immune tolerance. The classical MHC locus (6p21.3) 
3.6Mb contains at least 250 expressed genes. This locus is divided into the Class I and II 
regions that encode the antigen-presenting HLA proteins and Class III MHC that contains 
58 genes, located between Class I and II regions, only some its genes are of potential 
immunological interest (e.g. TNF-ǂ and TNF-ǃ, C4A, C4B and C2) and others which have 
poorly defined function. There is particularly strong linkage disequilibrium between genetic 
markers in this region which is strongly association with SLE in all GWA studies. It is 
therefore difficult to establish whether any associated variant is functional or simply 
observed due to linkage disequilibrium with functional polymorphisms elsewhere. It was as 
early as 1971 that Grumet et al. reported possible relationship between the HLA genes and 
SLE (Grumet, 1971). MHC alleles on 6p11–21 have shown the most significant association. 
Although the genetic structure of the MHC makes it a particularly challenging region to 
study, significant progress has been made over the last year. 
The Class II HLA genes are of particular importance, which encode antigen-presenting 
molecules that play a pivotal role in T-cell immunity. Most evidence has highlighted the DR 
loci, which are one of the Class II HLA gene complexes. The HLA-DRB1 gene is of particular 
importance in SLE. For the HLA-DRB1 gene, the serotype of DR2 holds the strongest 
evidence of disease association. Three class-II-containing-SLE-risk haplotypes (DRB1*1501 
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(DR2)/DQB1*0602, DRB1*0301) (DR3)/DQB1*0201, and DRB1*0801 (DR8)/DQB1*0402) are 
consistently associated with SLE in Caucasian populations by family-based TDT (van der 
Linden, 2001). 
Within the MHC class III region, there are genes that encode TNF-ǂ and -ǃ, lymphotoxin-ǃ, 
complement components C2 and C4, and heat shock protein 70 (Hsp70). In particular, TNFs, 
C2, and C4 have been implicated in SLE susceptibility. TNF-ǂ is a multifunctional 
proinflammatory cytokine involved in regulating a wide spectrum of biological processes 
including cell proliferation, differentiation, and apoptosis, while TNF-ǃ mediates a variety 
of inflammatory, immunostimulatory, and antiviral responses. Polymorphisms in these 
genes have been implicated in SLE susceptibility (Pan 2011 & Bettinotti, 1993). 
Complement component genes within the MHC class III region include C2, C4A, C4B, and 
factor B. These genes are closely linked and are usually inherited as a group known as 
complotype. Deficiencies in complement pathway genes C2, C4, C1q and C3 appear to cause 
SLE in some people (Kallel-Sellami, 2008). Polymorphisms in C2, C4A and C4B are in 
linkage disequilibrium with HLA-B and HLA-DR alleles (Alper, 2007) and may predispose 
to SLE. Also the complete deficiencies of the early components are highly associated with 
human SLE (Yu, 2007). A homozygous deficiency in one of the early complement 
components, including C1q, C1r, C1s and C4 in the classical activation pathway, alone can 
be strong enough to cause the disease, a situation similar to a single gene defect in an 
autosomal recessive disease. Respectively, 93% and 78% of patients with complete C1q and 
C4 deficiencies eventually develop SLE or a lupus-like disease (Yu, 2007 & Botto, 2002). In 
addition, the concordance rates for siblings with homozygous deficiency of C1q or C4 to 
develop SLE are 90% and 80%, respectively, which are even higher than the rate in 
monozygotic twins (26–60%) with other genetic defects (Tsao, 2008). Complete deficiency of 
complement C4 is among the strongest genetic risk factors for human systemic lupus 
erythematosus (SLE). Further work will be required to determine the effect arising from 
C4A. C4 is the most polymorphic protein of the complement system. It is encoded by two 
genes, C4A and C4B, which have minor sequence differences. The resulting proteins have 
different functional characteristics, with C4A better able to bind immune complexes 
(Schifferli, 1986). The C4 genes are inherited in a discrete ‘RCCX module’, which contains 
one C4 gene (either C4A or C4B) along with three neighboring genes (RP, CYP21 and TNX) 
(Yang, 1999). The Class III MHC carries between one and four copies of this module; hence 
each diploid genome has between two and eight C4 genes, which may be either C4A or C4B 
(Yang, 2007). Carrying less than two copies of C4A has been identified as a risk factor for 
SLE (Yang, 2007). 
The common European haplotype AH8.1 carries multiple variants that have been associated 
with SLE including DRB1*0301 (DR3), the TNF -308A allele and the C4A complement null 
allele. Many studies were unable to break down this haplotype below a 1Mb interval 
covering most of the Class II and II regions (Alper, 2007).  
7.2 PR domain containing 1, with ZNF domain - APG5 autophagy 5-like (PRDM1-ATG5 
region), (6q21) 
PRDM1 acts as a repressor of beta-interferon gene expression. The protein binds specifically 
to the PRDI (positive regulatory domain I element) of the beta-IFN gene promoter. While, 
the ATG5 candidate gene function is still obscure and needed to be determined however, 
both known to play important roles in immunity. Genome-wide association studies 
suggested the PRDM1-ATG5 gene region as a systemic lupus erythematosus (SLE)-
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associated locus both in Caucasian and Asian populations, presumably through 
upregulating gene expression (Zhou, 2011; Harley, 2008; Gateva, 2009; Han, 2009). 
Significant positive correlations with ATG5 expression were identified, suggesting ATG5 as 
a candidate gene in the region (Harley, 2008). Later GWAS from a Chinese population 
denied the association between polymorphisms in ATG5 and SLE, but replicated the 
association between the intergenic region of PRDM1-ATG5 (rs548234 and rs6568431) and 
SLE ((Han, 2009). At the same time, from Caucasian replication data, both PRDM1 
(rs6568431) and ATG5 (rs2245214) were suggested as candidate genes, because rs6568431 
was more close to PRDM1 and rs6568431 has an r2 of less than 0.1 with rs2245214. Meta-
analysis consolidated the association between rs548234 and SLE (p=1.28×10-16).  
7.3 Tumor necrotic factor α-induced protein 3 (TNFAIP3), 6q23 
The gene product of TNFAIP3 is a zinc-finger A20 protein, a ubiquitin-modifying enzyme, 
which is essential for proteasome degradation and termination of proinflammatory 
responses mediated by nuclear factor kappa B, thereby preventing inflammation. In 
humans, genetic surveys have suggested a role for TNFAIP3 in susceptibility to complex 
genetic autoimmune disorders, including systemic lupus erythematosus (SLE) (Graham, 
2008; Musone, 2008; Bates, 2005; Han, 2009). 
Genetic association between variants in TNFAIP3 and SLE suggest that alterations in activity 
and/or expression of TNFAIP3 influence SLE pathophysiology (Graham, 2008; Musone, 
2008; Bates, 2005; Han, 2009). Independent genetic associations of SLE and TNFAIP3 in 
European-ancestry (EA) subjects have been localized to a region 185 kb upstream of 
TNFAIP3 that was first identified with rheumatoid arthritis (Plenge, 2007; Thomson, 2007; 
Plenge, 2007), a region 249 kb downstream of TNFAIP3 and a 109 kb haplotype spans the 
TNFAIP3 coding region (Musone, 2008; Bates, 2005; Han, 2009) that includes a suggested 
causal coding variant in exon 3 (rs2230926 T>G; F127C) that reduces the ability of A20 to 
attenuate NF-κB signaling (Musone, 2008). 
Evidence for association with SLE was observed also for a variant within TNFAIP3 
(rs5029939, GWAS P value = 2.55×10−8) and two flanking SNPs (rs10499197, GWAS P  
value = 2.11×10−6; rs7749323, GWAS P value = 9.63×10−7) in strong LD with rs5029939 
(r2>0.95). A SNP located ∼185 kb upstream of TNFAIP3 reported to be associated with risk 
for RA (204,206) (rs6920220) demonstrated modest association in the SLE GWAS dataset 
(GWAS P value = 0.01) 
By fine mapping and genomic resequencing in ethnically diverse populations Adrianto I et 
al, fully characterized the TNFAIP3 risk haplotype and isolated a novel TT>A polymorphic 
dinucleotide (deletion T followed by a T to A transversion) associated with SLE in subjects 
of European (P = 1.58 × 10−8) and Korean (P = 8.33 ×10−10) ancestry (Adrianto, 2011). This 
variant, located in a region of high conservation and regulatory potential, bound a nuclear 
protein complex comprised of NF-κB subunits with reduced avidity. Furthermore, 
compared with the non-risk haplotype, the haplotype carrying this variant resulted in 
reduced TNFAIP3 mRNA and A20 protein expression. These results establish this TT>A 
variant as the most likely functional polymorphism responsible for the association between 
TNFAIP3 and SLE (Adrianto, 2011). 
One hundred and twenty seven (127) SNPs in the region of TNFAIP3 on 6q23 and 347 
ancestry informative markers (AIMs) in five diverse ethnic populations were analyzed by 
Adrianto I et al, They discovered a peak associations in European and Asian populations 
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were seen at markers rs6932056 and rs4896303 in 38 kb and 30 kb downstream of TNFAIP3, 
respectively (Adrianto, 2011). 
8. Chromosome 7 
8.1 Interferon regulatory factor 5 gene (IRF5), 7q32 
IRF5 is one of the key genes of the interferon (IFN)-ǂ pathway. IRF5 is a transcription factor 
that is responsible for the innate immune response during viral infection. IRF5 is important 
for trans-activation of type 1 IFN and IFN-responsive genes and for the production of pro-
inflammatory cytokines interleukins such as; IL-6, IL-12, and tumor necrosis factor- (TNF)] 
after toll like receptor (TLR) signaling induced by immune complexes containing self-
antigens and nucleic acids (Takaoka, 2005). IRF5 is one of the most strongly and consistently 
SLE-associated loci outside the MHC region in various ethnic groups and was detected 
using both candidate gene and GWAS approaches (Lee, 2009). Interest in type 1 (IFN- and -
) IFN pathways was stimulated by the discovery that there is a general up-regulation IFN-
inducible genes in SLE (Baechler, 2003 & Bennett, 2003). The best current genetic model 
proposes an SLE risk haplotype carrying multiple functional SNPs. Several SNPs in IRF5 
(rs2004640, rs752637, rs729302, rs10954213etc.) were first found to be associated with SLE in 
Caucasians (Niewold, 2008; Kim, 2009). 
In vitro functional evidence exists for at least two of these polymorphisms at SNP 
(rs2004640) creates a novel splice site in exon1B allowing the expression of a novel IRF5 
isoform (Graham, 2006 & Sigurdsson, 2005) while the second polymorphism (rs10954213) 
located in the 3’ UTR creates a functional polyadenylation site and hence a shorter and 
more stable gene transcript (Cunninghame, 2007). To our knowledge, the most consistent 
evidence of association for this gene with SLE, across different populations including, was 
observed in the rs2004640 T allele. A meta-analysis has been conducted to study the 
association of the rs2004640 T allele with SLE; it included 12 studies in Europeans and 
Asians, it has been concluded that this polymorphism is associated with SLE 
susceptibility across different ethnic groups (Lee, 2009). In addition, the gene has a 
polymorphic 30 bp indel (insertion/deletion) in exon 6, which contributes to the diversity 
in the isoform pattern of IRF5, and a 5 bp indel near the 5'UTR upstream of exon 1A 
(Sigurdsson, 2008 & Dideberg, 2007). 
To understand how IRF5 variants may predispose to SLE we need to understand the 
physiological role of the Type 1 IFN pathways. The majority of cells produce Type 1 IFNs as 
part of their early response to viral infection. Particularly large amounts are produced by 
plasmacytoid dendritic cells, perhaps stimulated by the recognition of viral RNA and DNA 
through TLR7 and TLR9. In SLE, it is possible that this is also triggered in response to 
inadequately cleared nucleic acid antigens released from apoptotic cells (Ronnblom, 2002). 
Type 1 IFNs exert a multitude of downstream effects on the immune system. Perhaps 
critically, they stimulate Th1 pathways and sustain activated T cells, while also lowering the 
threshold for B-cell activation through the B-cell receptor (BCR) and promoting B-cell 
survival and differentiation (Ronnblom, 2002; Braun, 2002; Le Bon, 2001; Marrack, 1999). It 
can therefore be seen that genetic variants that prolong or alter the actions of IRF5 could 
result in a prolonged proinflammatory response, and potentially break immunological 
tolerance. Interestingly, IRF5 signaling has also been shown to play a role in the regulation 
of cell cycle and apoptosis raising the possibility that susceptibility variants of IRF5 exert 
their effects at multiple levels (Barnes, 2003). 
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8.2 Ikaros zinc finger 1(IKZF), 7p12.2 
IKZF1 encodes a lymphoid restricted zinc finger transcription factor named Ikaros, which is 
critically important for the normal development of all lymphoid cells. It regulates 
lymphocyte differentiation and proliferation (Georgopoulos, 1994), as well as self-tolerance 
through regulation of B-cell receptor signaling (Wojcik, 2007). Data derived from both 
GWAS and large replication studies identified IKZF1 as a novel SLE susceptibility locus in 
Chinese and European-derived populations (Han, 2009). Yap et al. reported that IKZF1 was 
involved in the regulation of STAT4 in human T cells, which suggested that STAT4 and 
IKZF1 might cooperate with each other and play roles in the development of SLE (Yap, 
2005). Hu W. et al, demonstrated that IKZF1 mRNA expression levels in PBMCs from 
patients with SLE were significantly lower than those in healthy controls (Hu, 2011). 
Association of SLE and disease phenotype with IKZF1 was studied in Chinese Han origin 
SLE patients were the allele frequency of rs4917014 (IKZF1) was significantly different in 
two subphenotypes: renal nephritis (p=0.02) and malar rash (p=0.00038) (He, 2010). 
9. Chromosome 8 
Several studies have revealed association of SLE susceptibility to different genes within a 
700 kb region of locus 8p23.1 (Hom, 2008; Graham, 2008; Harley, 2008). This region contains 
several candidate genes, including BLK, XKR6, FAM167A/C8orf13 and C8orf12, these genes 
were in significant linkage disequilibrium (LD), making it difficult to determine whether the 
different reports are detecting the same association signal. Budarf ML et al. found significant 
association to both the BLK (rs2618476) and XKR6 (rs6985109) genes (Budarf, 2011). 
Although these two SNPS are separated by 620 kb, there is relatively strong correlation 
between them (r2=0.39), allowing the possibility that they may represent the same signal. 
Here in we will review the evidence of association of both genes BLK, XKR6 with 
susceptibility to SLE (Budarf, 2011).   
9.1 B lymphoid tyrosine kinase (BLK), 8p23.1
 
BLK encodes a nonreceptor tyrosine-kinase of the src family of proto-oncogenes, which 
mediates intracellular signaling and influences cell proliferation and differentiation. The 
human BLK gene was mapped to chromosome 8 at p23.1, and is expressed only in B 
lymphocytes (Drebin, 1995). The protein has a role in B-cell receptor signaling, B-cell 
development and tolerance of B cells (Reth, 1997). B cell receptor (BCR) signaling requires a 
tight regulation of several protein tyrosine kinases and phosphatases, and associated co-
receptors. Break of the balance between positive and negative signaling molecules likely 
modifies the BCR signaling thresholds. Such alterations, together with other factors, may 
contribute to the disruption of selftolerance in SLE. 
BLK has apparently become one of the most important and consistent non-MHC gene for 
SLE and the other autoimmune diseases across multiple ethnic groups and is one of three 
key genes (BLK, LYN and BANK) involved in BCR signaling found to be strongly associated 
with SLE proves the importance of this pathway in disease pathogenesis. B-lymphoid 
tyrosine kinase (BLK) was one of the top hit in more than one GWA analyses, while LYN 
was associated with high significance in the International Consortium for Systemic Lupus 
Erythematosus (SLEGEN) study only. BLK has been implicated in the pathogenesis of SLE 
and has been investigated in numerous ethnically diverse studies. 
GWAS in European-derived populations identified a SNP (rs13277113; located in the 
promoter region of BLK, maps to the intergenic region between FAM167A/C8orf13 and 
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BLK), of which allele A is associated with reduced expression of BLK but increased 
expression of FAM167A (previously referred to as C8orf13) in patients with SLE (Ito, 2010). 
Another BLK SNP (rs2248932), located 43 kb downstream of rs13277113, is also associated 
with SLE where the risk C allele of rs2248932 was associated with the lower levels of BLK 
mRNA expression (Zhang, 2010).  
Both SNPs have subsequently been confirmed as SLE-associated in Asian populations 
(Zhang, 2010 & Ito, 2009). Genotyping SNP rs2248932 in SLE patients of Chinese Han 
confirmed that SNP rs2248932 in BLK gene was significantly associated with SLE (P = 1.41 
x 10-8). The association of BLK in Chinese SLE patients was consistent with a dominant 
model. In contrast to the Caucasian, this risk allele was the major allele in the Chinese 
Han; the risk allele frequency was higher in Chinese Han than in Caucasian. No 
association was found between this SNP and any subphenotype of SLE.  Fan et al 
performed a meta-analysis to test the association of two SNPs rs13277113 and rs2248932. 
A significant associations of rs13277113 and SLE were observed for dominant model 
(AA + AG vs. GG, OR: 1.518), and recessive model (AA vs. AG + GG, OR: 1.553); so were 
rs2248932 and SLE for dominant model (TT + TC vs. CC, OR: 1.34), and recessive model 
(TT vs. TC + CC, OR: 1.34) (Fan, 2010).   
9.2 X Kell blood group precursor-related family, member 6 (XKR6), 8p23.1 
XKR6, a member of a novel family of PDZCBM containing proteins sharing homology 
with the C. elegans gene ced-8, which has been implicated in regulating the timing of 
apoptosis (Giallourakis, 2006). XKR6 contains an intronic microRNA, hsa-miR-598,  
which is highly expressed in human peripheral blood mononuclear cells, especially 
activated B-cells (Lawrie, 2008). Dissecting the relative contribution of XKR6 to SLE risk  
is likely to be a complicated undertaking, especially given that a polymorphic inversion 
under apparent selection pressure on 8p23 encompasses the XKR6, C8orf12, C8orf13,  
and BLK genes, all of which have been implicated in SLE risk in GWAS studies  
(Deng, 2008). 
9.3 Yamaguchi sarcoma viral (v-yes-1) related oncogene homolog
, 
LYN, 8q12.1 
LYN is a Src-tyosine kinase involved in B cell activation by phosphorylating the ITAM 
domain of the BCR-associated Ig ǂ/ǃ signaling molecules, in turn recruiting and activating 
the tyrosine kinase SYK, which initiates multiple activating signals. LYN also mediates 
inhibitory signals by phosphorylating inhibitory receptors such as CD22 and FcRIIb and 
may therefore have a critical role as a modulator of B-cell activation thresholds. In the 
Genome wide association studies (GWAS) of SLE, three B cell signaling molecules BLK, LYN 
and BANK1 (Hom, 2008; Kozyrev, 2008) were found to be associated with SLE. The best 
characterized functionally is LYN among the other two kinases (BANK, BLK) shown to be 
associated with SLE. These data suggest that aberrant regulation of B cell signaling may be 
one mechanism for generating hyper-responsive B cells, which might lead to aberrant B cell 
development, selection and ultimately influence the production of autoantibodies. 
Expression of Lyn is significantly decreased in both resting and BCR stimulated 
peripheral blood B cells from two-thirds of SLE patients compared to controls (Liossis, 
2001). Further, statistically significant alterations at the transcriptional level were 
confirmed by a 2.5-fold decrease in Lyn mRNA in SLE patients compared to healthy 
individuals. Another group analyzed the level and subcellular distribution of Lyn in SLE 
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B cells and found that slightly more than half of the SLE patients analyzed had reduced 
levels of Lyn protein, which was subsequently determined to be due to increased 
ubiquitination of the protein. Functional differences in LYN ubiquitination have been also 
associated with SLE risk (Flores-Borja, 2005). 
Two SNPs, rs7829816 and rs2667978, showed significant association in some of the cohorts 
tested, but failed to consistently replicate in all cohorts (Harley, 2008). Lu R. et al has 
performed one of the largest studies to examine the possible genetic association of LYN with 
SLE in multiple large populations of different ancestries (European-derived, African 
American and Korean). Their study has replicated a previously observed association with 
rs7829816 (Harley, 2008), however, data from Lu R. et al study suggested that this 
association is not a dominant lupus effect. The strongest and most consistent association 
found in this study was at rs6983130, which is within the first intron at the 5′ end near the 
primary transcription initiation site. This SNP showed the strongest association in the 
European-American female population. A strong gender influence was found with this SNP 
when analyzing only female subjects. Rs6983130 also showed associations with 
autoantibodies which is strongly associated with the development of SLE, specifically anti-
dsDNA, anti-chromatin, anti-52 kDa Ro and anti-Sm. 
10. Chromosome 10 
10.1 Mannose-Binding Lectin (MBL), (10q11.2-21) 
MBL is very similar to C1q in its structure and function. It is an important element of the 
innate immune system. MBL comprises a trimer of three identical polypeptides, and 
several trimmers further combine to form a bouquet-like structure (Holmskov, 1994). MBL 
recognizes carbohydrate patterns, found on the surface of a large number of pathogenic 
micro-organisms, including bacteria, viruses, protozoa and fungi and initiates the lectin 
pathway for opsonization and clearance of pathogens in an antibody-independent 
manner.  
MBL gene comprising four exons and there is only one single functional gene. The normal 
structural MBL alleles is named A, while the common designation for the 3 variant 
structural allele B (Gly54Asp), C (Gly57Glu) and D (Arg52Cys) are O. MBL expression is 
influenced by polymorphic sites in the upstream part of the MBL gene nucleotides 
substitutions at positions -550, -221 and +4. Absent or low levels of serum MBL is a result of 
these polymorphisms and might be associated with the development of SLE (Takahashi, 
2005 & Pradhan, 2010). Case-control genetic studies of MBL polymorphism were performed 
in various Ethnic groups. MBL genotyping in SLE confirmed that the MBL functional 
variants are associated with SLE (Ramasawmy, 2008). Serum MBL levels fluctuate during 
the course of SLE disease activity and MBL genotypes have been found to be useful in 
assessing the risk of infection during immunosuppressive treatment the majority of the SLE 
patients receive. 
Two possible explanations for associations between MBL deficiency and occurrence of SLE 
were proposed (Korb, 1997): (a) MBL can bind to and initiate uptake of apoptotic cells into 
macrophages (Ogden, 2001 & Okada, 2002), and abnormal clearance of apoptotic cells 
caused by MBL deficiency may result in overexpression of autoantigens; (b) viral infection is 
believed to be one of the causes of SLE (Okada, 2002), and MBL deficiency may lead to more 
frequent infections. 
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11. Chromosome 11 
11.1 Interferon regulatory factor 5 /PHD and RING-finger domains 1(IRF7/ PHRF1) 
locus, 11p15.5 
IRF7 is a transcription factor that can induce transcription of IFNα and in turn IFNα-induced 
genes downstream of endosomal TLRs, similar to IRF5 (Barnes, 2004). A SNP near IRF7 was 
found to be associated with SLE susceptibility in the International Consortium for SLE 
Genetics (SLEGEN) genome-wide association study (Harley, 2008). The associated SNP 
(rs4963128) was located 23 kb telomeric to IRF7 in a gene of unknown function named PHD 
and RING-finger domains 1 (PHRF1; also known as KIAA1542 or CTD-binding SR-like 
protein rA9). This SNP was in high linkage disequilibrium (r2 = 0.94) with the rs702966 SNP 
in IRF7 (Harley, 2008). The PHRF1 gene contains PHD-finger and RING-finger domains, 
and has not been functionally characterized to date. PHD and RING-finger domains both 
chelate zinc ions, and PHD domains are frequently found in proteins which mediate 
protein–protein interactions in the cell nucleus (Bienz, 2006). 
There is a hypothesizes that the SLE-associated variant discovered in the IRF7/PHRF1 locus 
in the SLEGEN study (International Consortium for Systemic Lupus Erythematosus 
Genetics, 2008) could be due to a polymorphism in IRF7 that predisposes to increased IFNα 
production. Then, Salloum R. et al have proven this hypothesis by analyzing serum IFNα in 
SLE patients as a quantitative trait to determine associations with haplotype-tagging SNPs 
in the IRF7/PHRF1 locus (Salloum, 2009). In a joint analysis of European American and 
Hispanic American subjects, the rs702966 C allele was associated with the presence of anti–
double-stranded DNA (anti-dsDNA) antibodies (P=0.0069). The rs702966 CC genotype was 
only associated with higher serum levels of IFNα in European American and Hispanic 
American patients with anti-dsDNA antibodies (joint analysis P = 4.1 × 10−5) (International 
Consortium for Systemic Lupus Erythematosus Genetics, 2008). However, the rs702966 C 
allele was not associated with anti-dsDNA in the African American subjects, and no other 
significant associations were seen in this group. In African American patients, the rs4963128 
T allele downstream of IRF7 was associated with the presence of anti-Sm antibodies  
(P = 0.0017), where subjects with the rs4963128 CT and TT genotypes had higher IFNα levels 
than those with the CC genotype (P = 0.0012). The striking differences observed within the 
African American cohort separated by the presence or absence of anti-Sm antibodies suggest 
2 independent patterns of association with IRF7/PHRF1 variants, which cannot be 
explained by European admixture at the locus. It is possible that the rs4963128 T allele 
marks a particular element in African-derived chromosomes that associates with anti-Sm 
antibodies and is not present in the other ancestral backgrounds (Salloum, 2009). Salloum R. 
et al hypothesized that the rs702966 C allele and elements in linkage with it may function 
similarly across all ancestral backgrounds, although the effect of the anti-Sm–rs4963128 T 
allele interaction on serum levels of IFNα in African Americans is independent of the effect 
at the rs702966 C allele (Salloum, 2009). 
12. Chromosome 16 
12.1 Integrin αM (ITGAM), 16p11.2 
ITGAM is a single-pass type I membrane protein predominantly expressed primarily on 
neutrophils, macrophages and dendritic cells that is involved in various adhesive 
interactions to stimulated endothelium, and also in the phagocytosis of complement coated 
particles. Together with integrin chain ǃ2, ITGAM forms a functionally active heterodimer, 
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the integrin ǂMǃ2 molecule to form the cell surface receptor, known as complement 
receptor 3 (CR3) or Mac-1, can bind a variety of ligands including intercellular adhesion 
molecule 1 (ICAM-1), the C3bi fragment of activated complement C3, fibrinogen, and factor 
X. ITGAM is perhaps more familiarly known as CD11b or CR3, and it thereby takes part in 
the uptake of complement-coated particles and the clearance of immune complexes. 
The identification of ITGAM as a major susceptibility gene was perhaps the greatest surprise 
of the GWA analyses because it has been subject to expression studies in the past with little 
convincing evidence for a role in SLE (Harley, 2008 & Hom, 2008). A non-synonymous SNP 
in ITGAM, rs1143679, functional mutation results in an Arg77His (R77H), was first 
associated in European and African descendants SLE patients, where the G allele 
contributes to disease susceptibility (Nath, 2008 & Han, 2009). This amino acid does not lie 
within any known ligand binding site, but may alter the confirmation of the  I/A domain to 
which many ligands do bind. This variant could therefore influence leucocyte trafficking 
mediated via ICAM-1, or equally it could influence the CR3-mediated uptake of apoptotic 
cells or immune complexes. Functional data is awaited with interest. However, the 
consistent association of rs1143679 was not replicated in Asian population (Korean and 
Japanese) because this SNP was monomorphic for ‘G’ allele (Han, 2009). This result suggests 
that the genetic association of ITGAM with SLE is unlikely in Asians. However, another 
group studied Chinese SLE patients living in Hong Kong and found that rs1143679 was 
associated with SLE, and another related SNP in the gene, rs1143683, was also identified 
(Yang, 2009). Therefore, it needs to be confirmed in larger number of SLE case–controls in 
Korean and Japanese populations. 
12.2 Deoxyribonuclease DNase I, 16p13.3 
DNase I may be the most important nuclease for the removal of DNA from nuclear 
antigens. Several lines of evidence suggest that defects in DNase I activity play a role in SLE 
pathogenesis. Studies in SLE patients and in mouse models support the involvement of 
DNase I among the genes involved in the clearance of apoptotic cells. The first evidence was 
reported by Chitrabamrung et al. (Chitrabamrung, 1981) more than two decades ago. These 
authors found decreased DNaseI activity in patients with SLE. It has been shown that a 
DNaseI knockout mouse develops a lupus-like syndrome (Napirei, 2000) and a nonsense 
mutation on the DNASEI gene leading to a non-functional protein has been identified in two 
Japanese girls with SLE. These girls had very low DNaseI activity and high titers of anti-
nucleosome and anti-double-stranded DNA (dsDNA) antibodies. Subsequent analysis of 
several series of SLE patients from different populations showed that this mutation is 
extremely rare. Bodan˜o A et al., have described two Spanish SLE patients with very low 
serum DNase I activity harboring three new mutations in the DNASEI coding sequence that 
account for the reduced enzymatic activity (Bodan˜ o, 2004). The frequency of these new 
mutations was below 1% both in SLE patients and in the population. Bodan˜o A. et al. also 
found other DNASEI single-nucleotide polymorphisms (SNPs) but there was no evidence 
suggesting a functional role for them. These studies support the involvement of DNase I in 
the pathogenesis of SLE. 
In a Korean SLE population, 16 SNPs from the DNaseI were studied using a case–control 
approach. In parallel, common autoantibodies were also examined for the same population. 
None of the SNPs were in significant association with SLE, however, a non-synonymous 
SNP in exon 8, namely rs1053874 (which was also known as +2373A/G, and which causes 
Gln244Arg substitution), was significantly associated with an increased risk of the 
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production of anti-RNP and anti-dsDNA (Shin, 2004). However, the same SNP (+2373A/G) 
has shown association between the GG allele and SLE susceptibility in Spanish population, 
but no association with the majority of antinuclear antibodies (anti-dsDNA, anti-ssDNA and 
anti-RNP) and no effect on DNase I activity (Bodaño , 2006). This discrepancy could be 
related to heterogeneity between the populations. 
13. Chromosome 17 
13.1 Monocyte chemo-attractant protein 1 (MCP1), 17q11.2-12 
MCP-1, currently also designated CCL2, encodes a ǃ-chemokine that recruits monocyte, 
eosinophils, and memory T cells to inflammatory sites, to regulate adhesion molecule 
expression and T-cell functions in acute and possibly chronic inflammation (Charo, 2004). 
Evidence in human and animal studies suggests a significant role of MCP-1 in the 
progression of glomerular and tubulointerstitial injuries and glomerulonephriti in patients 
with SLE (Stahl, 1993; Rovin, 1996; Saitoh, 1998; Rovin 1998). In particular, MCP-1 has been 
shown to be pathogenic for kidney injury in murine lupus nephritis (Shimizu, 2004), and 
reported to be involved in glomerulonephritis in SLE patients, in which elevation of serum 
MCP-1 correlates with disease activity (Tesar, 1998). An increased urine MCP-1 (uMCP-1) 
level was detected in SLE patients during active renal disease (Rovin, 2005). 
SNP (rs1024611) -2518A/G and G/G in MCP1 promoter region may modulate the levels of 
MCP-1 expression and increased susceptibility to SLE and lupus nephritis in patients from 
North America (Tucci, 2004). However, the Involvement of the MCP-1 –2518 A>G promoter 
polymorphism in SLE development and its contribution to some clinical manifestations of 
SLE remains controversial (Tucci, 2004; Aguilar, 2001; Hwang, 2002; Kim, 2002; Brown, 2007; 
Liao, 2004; Ye, 2005). In a Spanish study for example, −2518G polymorphism is noted to be 
associated with cutaneous vasculitis but not SLE or lupus nephritis as genotyping of 
−2518A/G polymorphism shows no difference in allelic or genotype frequencies in SLE 
patient and healthy controls (Aguilar, 2001). Further investigation is needed to delineate if 
ethnic heterogeneity contributes to this gene polymorphism and SLE susceptibility. 
14. Chromosome 19 
14.1 Tyrosine kinase 2 (TYK2), 19p13.2 
TYK2 is part of the Janus kinase that binds to the interferon (IFN)- receptor (IFNAR),  
on the cell surface of IFN-producing cells. Binding of IFN- to its receptor, leads to  
the phosphorylation and therefore activation of TYK2 (Richter, 1998). Active TYK2  
then phosphorylates IFNAR to allow binding of STAT3 and STAT5 (David, 2002) which 
leads to expression of IFN-ǂ. Deficiency of TYK2 leads to defects of multiple cytokine 
pathways, including type I interferon, IL-6, IL-10, IL-12, and IL-23, and to impaired T-
helper type 1 differentiation and accelerated T helper type 2 differentiation (Minegishi, 
2006). More research needed to clarify which of these pathways is critically affected by the 
TYK2 risk allele.  
TYK2 gene has been linked to the formation of anti-dsDNA antibodies of Caucasian SLE 
patients (Namjou, 2002). TYK2 rs2304256 was associated with increased risk of discoid lupus 
erythematosus (P=0.012). In a joint linkage and association study of 44 SNPs in 13 genes 
from type I IFN pathway in the Scandinavian population, TYK2 and interferon regulatory 
factor 5 (IRF5) genes displayed strong association with SLE susceptibility (Sigurdsson, 2005). 
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The most remarkable result from this study has probably been the association signal 
observed with the rs2304256 nonsynonymous SNP of TYK2 (OR = 0.79) because this has 
been a controversial SLE genetic factor. The rs2304256 SNP introduces a valine to 
phenylalanine change in the Janus homology domain 4 of TYK2 whose functional relevance 
has not yet been tested. This nonsynonymous SNP showed the strongest association among 
the 11 TYK2 SNPs studied in Scandinavian families (Sigurdsson, 2005), but was not 
associated in a study of UK families (Cunninghame, 2007). This latter study, however, found 
association with another TYK2 SNP (rs12720270) that was not associated in the 
Scandinavian study. Finally, the International Consortium for Systemic Lupus 
Erythematosus Genetics (SLEGEN) GWA study excluded association with the rs12720270 
SNP (the rs2304256 SNP was not included in the GWA panels)( International Consortium 
for Systemic Lupus Erythematosus Genetics, 2008).  
TYK2 single nucleotide polymorphisms (SNPs), rs2304256, rs12720270 and rs280519, were 
genotyped in the Japanese population by Kyogoku C et. al. in a case-control association 
study. Linkage disequilibrium (LD) among TYK2 SNPs was examined and no association 
was revealed with SLE therefore it was concluded that TYK2 is not a genetic risk factor for 
SLE in a Japanese population (Kyogoku, 2009). 
15. Chromosome X 
15.1 Interleukin-1 receptor-associated kinase 1/Methyl-CpG-binding Protein 2 locus 
(IRAK1/MECP2), Xq28 
IRAK1, a serine–threonine protein kinase, regulates multiple pathways in both innate and 
adaptive immune responses by linking several immune-receptor- complexes to TNF 
receptor-associated factor 6 in mouse models of lupus, Irak1 is shown to regulate nuclear 
factor κB (NFκB) in TCR signaling and Toll/interleukin-1 receptor (TLR) activation, as well 
as the induction of IFN-ǂ and IFN-Ǆ, (Jacob, 2009) implicating IRAK1 in SLE. In a study of 
four different ethnic groups, multiple SNPs within IRAK1 were associated with both adult-
onset and childhood-onset SLE (Jacob, 2009). The identified polymorphism C203S in IRAK1 
is not in any known functional domain, therefore it was suggested that the association may 
actually be with its neighbor, methyl-CpG-binding protein 2 (MECP2). 
MECP2 is an X-linked gene located in a region of LD with IRAK1, encoding a protein that 
represses transcription from methylated promoters, has also been associated with lupus. 
Polymorphisms in MECP2 may have relevance to the epigenetic DNA methylation changes 
found in lupus and discussed below. There is evidence for altered methylation in SLE, 
(Webb, 2009) as well as differential expression of potentially methylated genes, (Pan, 2009) 
although, as with IRAK1, a contributing causative SNP is not immediately obvious. Indeed, 
it is possible that both of these strong candidates contribute to the effect. 
A large replication study in a European-derived population confirmed the importance of 
this region (IRAK1–MECP2) to SLE. The location of IRAK1 and MECP2 on the X 
chromosome raises the possibility that gender bias of SLE might, in part, be attributed to sex 
chromosome genes. Further work is required to identify the causal variants (Sestak, 2011). 
15.2 Toll-like receptor (TLR7), Xp22.2 
TLR7, the protein encoded by this gene is a member of the Toll-like receptor (TLR) family 
which is single transmembrane cell-surface receptors expressed on many types of cells 
including macrophages and dendritic cells, plays a fundamental role in pathogen 
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recognition and activation of innate immunity. TLRs generally exist as homodimers. They 
are highly conserved from Drosophila to humans and share structural and functional 
similarities. TLR are activated by molecules associated with biological threat and are highly 
specific towards evolutionary conserved entities on microbes, such as bacterial cell-surface 
lipopolysaccharides, flagella and unmethylated CpG islands.  
Activation of toll-like receptors initiates downstream signaling cascades, initially via the 
adapter molecules MyD88, Trap, Trif and Tram, leading to NF-kappa-B activation, cytokine 
secretion and the inflammatory response, regulate intracellular kinases and gene expression. 
The signaling cascade coupled to toll-like receptor activation is very similar to that of 
interleukin-1 receptor (IL-1R) activation. It has been suggested that some toll-like receptors 
may have endogenous ligands, such as Hsp60 and fibrinogen, and this has promoted 
speculation that endogenous toll-like receptor activators may have a pathological role in 
autoimmune disease. TLRs play an important role in the pathogenesis of SLE (Vollmer, 2005 
& Christensen, 2006). The role of nucleic acid binding TLR7 has become quite apparent in 
both SLE animal models and human patients. This receptor promotes autoantibodies and 
cytokines responsible for chronic inflammation (Christensen, 2007 & Savarese, 2008). A 
recent fine mapping of the 23-kb TLR7 region using 11 SNPs in 1434 SLE cases of Eastern 
Asian descent versus 1591 controls showed the association of two TLR7 SNPs with SLE 
(rs5935436 in the promoter, p=1.8x10-3; rs3853839 in the 3’-UTR, p=6.7x10-4) (in press). 
16. Epigenetics involvement in the pathology of SLE  
The controversy, we came cross in the previous section, in the association of 
immunologically related genes with susceptibility to SLE and the incomplete concordance in 
monozygotic twins affected with SLE, while they carry the same SLE susceptibility genes, 
are clear indications that genetics is not the only factor that influences susceptibility to SLE. 
This means that some non-genetic factors can modify gene expression through epigenetic 
mechanisms, potentially contributing to SLE. The field of epigenetics is rapidly growing 
especially in studying autoimmune diseases. Epigenetics is the study of heritable 
modifications in gene function that alter the phenotype without modifying the genetic 
sequence, these modifications result in the activation or complete/partial gene silencing 
(Hirst, 2009). It is becoming clear that epigenetic modifications contribute to a variety of 
pathogenetic processes in which environmental and genetic factors are involved. Much of 
the variability in severity, organ involvement, and response to therapy among patients with 
systemic lupus erythematosus (SLE) is blamed on differences in gene expression. That, in 
turn, is due to epigenetic mechanisms, one of the "master regulators" of gene expression. 
Accumulating epidemiological, clinical, and experimental evidence supports the conclusion 
of the critical role of epigenetic factors in immune programming. Compelling evidence has 
been gathered supports a role for epigenetic alterations in the pathogenesis of SLE. For 
example, inhibiting DNA methylation in normal CD4+ T cells induces autoreactivity, and 
these autoreactive cells promote autoantibody production. Furthermore, transferring 
hypomethylated T cells into syngeneic mice causes a lupus-like disease (Richardson, 1990 & 
Yung 1997). Understanding this mechanism provides the basis for clarifying how the 
complex interactions of the genome and epigenome shape immune responses and maintain 
immune tolerance to self-antigens.  
In this section we will discus, in brief, some of the epigenetics mechanisms that are involved 
in the SLE pathogenesis. These mechanisms play an essential role in gene regulation  
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Gene  locus function P-values ORs 
PTPN22  1p13 T-cell signaling <1x10-5 - 
5.2x10-6 
1.49-1.53 
FCGR2A  1q21-23 Immune complex clearance  Fc Receptor 0.0016 -
6.78x10-7  
1.30-1.35 
FCGR3B  1q23.3  Immune complex clearance  Fc Receptor 2.7x10-8 2.21c 
FcGR3A 1q23.3  Immune complex clearance  Fc Receptor  1.6 
CRP 1q23.2 sensitive marker of inflammation 6.4x10-7  
TNFSF4  
 
1q25.1 T-cell signaling over: 1.91x10-6 over: 1.63 
(T/U) and 
1.28b 
NMNAT2  1q25.3 Catalyzes the formation of NAD(+)from 
nicotinamide mononucleotide (NMN) and 
ATP. 
1x10-10 1.18 
IL10* 1q31–q32 1q24 4.0×10 −8  1.2 
TLR5 1q41-q42 innate immunity    
STAT4  2q33 TLR–IFN signaling 2.8x10-9 - 
8.96x10-14 
1.53-1.50 
PDCD1 
(CD279) 
2q37 pro-B-cells differentiation  1.2 
CTLA4 
(CD152) 
2q33.2 transmits an inhibitory signal to T cells   
PXK  3p14.3 Bind and modulates both Na, 
K-ATPase enzymatic and ion pump 
activities  
7.10x10-9 1.25  
BANK1  4q24 B-cell signaling 3.7x10-7 1.38 
TNIP1 5q33 TNF–NFκB signaling  1.3 
The MHC  6p21.3 T-cell signaling 2.71x10-21-
1.7x10-52 
2.01-2.36 
ATG5  6q21  1.36x10-7 1.19 
PRDM1 6q21 B-cell signaling 1.74×10 −8  1.3 
TNFAIP3 6q23 TNF–NFκB signaling 2.9x10-12 1.7 
IRF5  7q32 TLR–IFN signaling 1.65x10-11 -
3.61x10-19 
1.54-1.72 
ICA1  7p21.3  1.90x10-7 1.32 
IKZF1 7p12 B-cell signaling  1.4 
BLK  8p23.1 T-cell signaling 1x10-10 -7x10-10 1.22-1.39 
XKR6  8p23.1  2.51x10-11 1.23 
LYN  8q12.1  5.4x10-9 1.30 
C8orf12  8p23.1  miscRNA  gene 4.00x10-10 1.22 
BLK–
FAM167A
–XKR6 
locus 
8p23.1 B-cell signaling 1.7x10-8 1.2-1.6 
MBL 10q11.2-
21 
element of the innate immune system   
KIAA1542 
(near IRF7)  
11p15.5 Interferon and TLR7 ⁄ 9 Signaling 3.00x10-10 1.28 
ITGAM  16p11.2 Neutrophil activity 3x10-11 -
1.61x10-23 
1.33-1.62 
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CD226 18q22.3 member of the Ig-superfamily    
TYK2 19p13.2 Janus kinases (JAKs) protein 
interferon signaling pathway 
  
UBE2L3  22q11.2 encodes a member of the E2 ubiquitin-
conjugating enzyme 
7.53x10-8 1.22 
SCUBE1  22q13.2 adhesive molecule 1.21x10-7 1.28 
MECP2  Xq28  Chromosomal protein that binds to 
methylated DNA 
1.2x10-8 1.39 
IRAK1 Xq28 responsible for IL1-induced upregulation 
of the transcription factor NF-kappa B 
  
TLR7 Xp22.2 innate immunity   
Table 1. Top SLE candidate genes categorized by chromosomal location. 
through covalent modifications of DNA and histones, and determine regional chromatin 
structure with consequences on gene expression. We will also discuss the involvement of 
MicroRNAs (miRNAs) as an epigenetic factor involved in the pathology of SLE. 
16.1 Histone covalent modification 
The basic chromatin subunit is the nucleosome, which consists of DNA wrapped twice 
around a histone core. Nucleosomes are then organized into higher order structures forming 
chromatin fibers (Felsenfeld 2003). Chromatin in its native form is tightly compacted and 
inaccessible to transcription factors and the transcription initiation machinery. However, 
histone “tails” protrude from the nucleosome, and are covalently modified by acetylation, 
methylation, phosphorylation, ubiquitination, and SUMOylation (SUMO (small ubiquitin-related 
modifier) (Felsenfeld 2003). These modifications serve as signals, referred to as the “histone 
code”, that initiate a number of processes including the localized remodeling of chromatin 
from a compact, transcriptionally silent configuration to a more open structure accessible to 
the transcription initiation machinery. 
16.2 DNA methylation and autoimmunity 
DNA methylation refers to the methylation of cytosines in CpG pairs (cytosine and guanine 
residues separated by a phosphate, which links the two nucleosides together in DNA). Most 
CpG pairs in the mammalian genome are methylated, with some unmethylated pairs found 
in the regulatory elements of active genes. Most unmethylated CpGs are found in GC-rich 
sequences, termed CpG islands. CpG islands contain multiple binding sites for transcription 
factors, and serve as promoters for the associated gene. Methylation of these promoters can 
lead to gene silencing where transcriptionally active chromatin is characterized by 
unmethylated DNA. Convincing evidence indicates that DNA can be actively demethylated 
and therefore affect gene expresssion. For example, several CpG pairs in the IL-2 promoter 
demethylate within 20 minutes of T-cell stimulation, prior to initiation of DNA synthesis 
(Bruniquel, 2003).  
DNA methylation is catalyzed by the enzyme DNA methyltransferases (DNMTs) while and 
histone acetylation is controlled by histone acetylases (HATs) and deacetylases (HDACs). It 
is hypothesized that the processes of DNA methylation and histone deacetylation work 
together through the formation of DNMT/HDAC transcriptional repressor complexes that 
work in silencing gene expression through establishing a repressive chromatin environment 
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(Cameron, 1999). However, DNMTs and HDACs lack DNA-binding domains, and are 
therefore dependent on transcription factors (TFs) for their recruitment to DNA. Zhao M et 
al. set out a study to uncover mechanisms underlying the hypomethylation and 
hyperacetylation of genes involved in lupus autoimmunity by investigating the involvement 
of specific TFs. They assessed the activities of 225 TFs in CD4+ T cells from SLE patients 
relative to healthy controls using a newly developed screening method (Qiao, 2008), and 
found that the activity of regulatory factor X 1 (RFX1) is significantly downregulated in SLE 
CD4+ T cells (Zhao, 2010). Follow-up analyses confirmed the result of Zhao M et al. study 
and further revealed that both the expression and activity of RFX1 protein are reduced in 
SLE CD4+ T cells. Zhao M et al (Zhao, 2010) also provided evidence indicating that RFX1 
recruits the co-repressors HDAC1 and DNMT1 to the promoter region of CD11a and CD70, 
thus regulating their expression in CD4+ T cells. Taken together, our findings indicate that 
reduction of RFX1 plays an important role in inducing autoreactivity and autoantibody 
overstimulation in SLE. 
In addition, DNA hypomethylation appears to induce CD4+ T cell autoreactivity and the 
inhibition of DNA methylation with 5-azacytidine caused CD4+ T-cell autoreactivity. This 
lupus-like autoimmunity correlated with overexpression of ITGAL (CD11a) and TNFSF7 
(CD70) (Lu, 2002 & 2005). CD11a and CD70 overexpression in these CD4+ T cells is 
associated with hypomethylation of their respective promoters (Lu, 2002 & 2005). CD11a is 
the alpha chain of the heterodimeric integrin lymphocyte function-associated antigen-1 
(LFA-1) (CD11a/CD18) (ITGAL/Integrin beta-2). Overexpressing LFA-1 by transfection 
caused an identical autoreactivity (Yung, 1996).LFA-1 plays a central role in adhesive 
interactions between T cells and other immune system cells including macrophages, 
dendritic cells and B cells. This protein is also essential for the recruitment of leukocytes into 
sites of inflammation, antigen-specific T cell activation, helping B cell, as well as alloreactive, 
cytotoxic T cell and natural killer responses (Shimaoka & Springer, 2003). LFA-1 deficient 
lupus mice have significantly increased survival, decreased anti-DNA autoantibody 
formation, and reduced glomerulonephritis (Kevil, 2004). CD70 is expressed on activated T 
cells and increases pokeweed mitogen (PWM)-stimulated immunoglobulin (Ig) G synthesis, 
indicating B cell costimulatory functions (Kobata, 1995). Demethylated, autoreactive CD4+ T 
cells overstimulate antibody production by B cells and kill macrophages (Richardson, 2007), 
relaeasing apoptotic nuclear material that stimulates lupus-like autoantibodies (Denny, 
2006). T-cell hypomethylation correlates with disease activity in SLE, suggesting that DNA 
hypomethylation may be a key player in the pathogenesis of the disease (Corvetta, 1991). 
Furthermore, CD4+ lymphocytes undergo global histone H3 and H4 deacetylation and 
consequent skewed gene expression. Although multiple lines of evidence highlight the 
contribution of epigenetic alterations to the pathogenesis of lupus in genetically predisposed 
individuals, many questions remain to be answered. Attaining a deeper understanding of 
these matters will create opportunities in the promising area of epigenetic treatments. 
16.3 MicroRNAs (miRNAs) and autoimmunity 
MicroRNAs (miRNAs) are newly discovered, small (about 23-nucleotide),  noncoding 
ribonucleic acids (RNAs) that function in the posttranscriptional regulation of about 30% of 
mRNAs by binding to their 3′-untranslated region (3′-UTR), thus targeting them for 
degradation or translational repression. miRNA are known to regulate cellular processes 
such as apoptosis, cell cycle, differentiation, and immune functions. The powerful gene 
regulatory role of miRNAs is now well recognized, where the recent discovery of the gene-
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regulatory role of miRNAs has led to a paradigm shift in the understanding of expression 
and function of the mammalian genome. The field of miRNA research gained widespread 
attention with the recognition of aberrant expression and/or function of miRNAs in a broad 
range of human diseases including autoimmune diseases (Pauley, 2009). 
Recent research evidence has emerged showing the critical role of miRNAs not only for the 
development of the immune system but also for the function of both innate and adaptive 
arms of the immune system (Taganov, 2007; Xiao, 2009; Gantier, 2007; O’Connell, 2010; 
Lodish, 2008; Sonkoly, 2008; Baltimore, 2008). Using state of the art quantitative mass 
spectrometry two investigators measured the response of thousands of proteins after 
introducing microRNAs into cultured cells and after knockdown mir-223 in mouse 
neutrophils. Their results are consistent with each other and demonstrate that changes in the 
level of a single miRNA may have a significant impact on the levels of hundreds to 
thousands of proteins (Baek, 2008). These important studies are the first to show the impact 
of microRNAs on the proteome which indicated that for most interactions microRNAs act as 
rheostats to make fine-scale adjustments to protein output (Baek, 2008 & Selbach, 2008). 
Tang et al have shown that miR-146 regulates the level of at least TRAF6, IRAK1, STAT-1, 
and IFN regulatory factor 5 (IRF-5), all of which are important for the IFN pathway (Tang, 
2009). The reported reduction of miR-146 in PBMCs from SLE patients (Tang, 2009) will 
likely affect the levels of these factors significantly and contribute to overexpression of type I 
IFN and, thus, disease activity. 
It is intriguing that independent studies have demonstrated an increased level of miR-146 in 
RA patients, but a decreased level in SLE patients, as compared with healthy controls. Given 
that RA and SLE are both systemic rheumatic diseases, one may be surprised by the finding 
that miR-146 levels are contradictory in these diseases, and yet, it should not be surprising, 
since this may simply be reflecting a difference in the overall cytokine profiles between the 
two diseases, with type I IFN playing a dominant role in SLE, whereas TNFǂ, interleukin-1 
(IL-1), and IL-6 are the principle cytokines in RA. In the coming years, one can expect 
research reports on miRNA expression in many other autoimmune diseases, as well as 
more-complete profiling data, with disease activity correlations or a lack thereof. 
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